9I制作厂免费

Abstract:

The G枚tte lab has a longstanding interest in the study of viral polymerases. The focus has been on the biological function of these enzymes and the discovery and development of antiviral drugs. While at 9I制作厂免费 (2000-2014), his work was centered around human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT), human cytomegalovirus (HCMV) DNA polymerase and hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp). He contributed to the discovery of novel classes of HIV-1 RT inhibitors and studied the genetic, biochemical and structural basis of drug resistance. Since 2024, at the University of Alberta, he changed directions and started to focus on polymerases of viruses with high epidemic potential. His lab was the first to express, purify and show inhibition of the Ebola virus polymerase complex, the 450 kDa Crimean-Congo hemorrhagic fever virus (CCHFV) polymerase and the SARS-CoV-2 polymerase complex. They have now established a library of ~50 viral polymerases representing important families of retroviruses, DNA and RNA viruses. This is a unique platform for the evaluation of polymerase inhibitors, which was proven successful in the early days of the pandemic. G枚tte鈥檚 lab and collaborators from Gilead Sciences published in February and April of 2020 the mechanism of action of remdesivir, a C-linked adenosine analog that targets the polymerase of coronaviruses. These studies showed that remdesivir, when compared with other available nucleotide analogs, was by far the most potent compound against the polymerase of the new virus. Remdesivir was later approved as the first antiviral drug for the treatment of COVID-19. More recently, he contributed to the development of a novel nucleosides with potent activity against a broader spectrum of respiratory viruses. However, effective nucleoside analogs that target the polymerase of influenza viruses remain elusive.听听听

听

Bio:

Matthias G枚tte obtained his PhD degree in 1997 at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. In 2000, following his postdoctoral training with Mark Wainberg at the Lady Davis Institute for Medical Research in Montreal, he joined the faculty at 9I制作厂免费 in the Department of Microbiology & Immunology. In 2014, he accepted the position as chair of the Medical Microbiology & Immunology Department (MMI) at the University of Alberta (UofA) in Edmonton, Alberta. G枚tte has been recognized for his expertise in the study of viral polymerases, antiviral drugs and the broader field of pandemic preparedness. Early in the COVID-19 pandemic, his lab elucidated the mechanism of action of the nucleoside analog remdesivir. In 2020, he was invited to the 2020 National Institutes of Health (NIH) SARS-CoV-2 Antiviral Therapeutics Summit and served on the Canadian COVID-19 Therapeutics Task Force. In 2022-2025, he was an investigator of three NIH-funded Antiviral Drug Discovery (AViDD) Centres for Pathogens of Pandemic Concern, led by the University of North Carolina (UNC), Scripps Research in La Jolla, and the University of California San Francisco (UCSF). In 2023, he completed his second term as the chair of MMI and is currently the Director of UofA鈥檚 pandemic preparedness program SPP-ARC (Striving for Pandemic Preparedness - The Alberta Research Consortium).听听